Source: Annual Congress 2013 –Asthma drugs: new findings
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Dissanayake, B. Grothe, T. McIver, K. Kaiser (Cambridge, United Kingdom; Muttenz, Switzerland). Validation of FEV₁ spirometric endpoints as a measure of the anti-inflammatory and bronchodilatory effects of fluticasone/formoterol combination therapy. Eur Respir J 2013; 42: Suppl. 57, 4131

Member's Comments

No comment yet.

Related content which might interest you: Knemometry assessment of short-term lower leg growth in children with asthma treated with fluticasone propionate/formoterol combination therapy Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015 Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: Lung function and safety Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Effect of breathing parameters on lung dose in case of two combination drugs used in asthma and COPD therapy Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 The add-on effect of tiotropium bromide to ICS/LABA combination inhaler for the patients with severe uncontrolled asthma Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD Source: International Congress 2014 – Markers Year: 2014 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 Evaluating the effects of inhaled corticosteroid on insulin sensitivity in asthmatic patients Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Tiotropium as add-on to inhaled corticosteroids significantly improves asthma control as reflected by the ACQ responder rate Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Comparable effectiveness of budesonide/formoterol combination and fluticasone for the treatment of cough variant asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 A double blind placebo controlled study to assess the effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients using novel biomarkers Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 The mechanisms of antiinflammatory effect of mucolytic therapy Source: International Congress 2014 – Predictors Year: 2014 Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 The fixed-dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014